{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:21:13Z","timestamp":1782375673739,"version":"3.54.5"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anaplastic lymphoma kinase (ALK) fusions can be found in different solid tumors. This study aims to describe the clinical characteristics and investigate survival outcomes of patients with ALK fusion-positive solid tumors (excluding non-small cell lung cancer [NSCLC]) treated with standard-of-care therapies in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Data for patients with metastatic solid tumors (excluding NSCLC) who had \u22651 Foundation Medicine comprehensive genomic profiling (CGP) test between January 1, 2011 and September 30, 2023, were obtained from a nationwide (US-based) de-identified multi-tumor clinico-genomic database. Patients with ALK wild-type (ALK-WT) tumors were matched with patients with ALK fusion-positive tumors (4:1 ratio) using pre-specified baseline characteristics. Two models were used to analyze survival outcomes: Model 1 used the CGP report date as the index date; Model 2 used the date of metastatic diagnosis as the index date (including adjustment for immortal time bias).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 22 and 88 patients were included in the ALK fusion-positive and ALK-WT cohorts, respectively. Co-alterations were rare in the ALK fusion-positive cohort. Median overall survival was consistently lower in patients with ALK fusion-positive tumors compared with patients with ALK-WT tumors, across all analyses (hazard ratios between 1.8 and 2.0).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Data from this study suggest that ALK fusions have a negative prognostic effect in metastatic solid tumors and highlight the need for further investigation of ALK inhibitors in the tumor-agnostic setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf005","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:49:33Z","timestamp":1746712173000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-world characteristics and survival outcomes of patients with metastatic <i>ALK<\/i> fusion-positive solid tumors treated with standard-of-care therapies"],"prefix":"10.1093","volume":"30","author":[{"given":"Shirish M","family":"Gadgeel","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology, Henry Ford Cancer Institute\/Henry Ford Health , Detroit, MI 48208 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Fajardo","sequence":"additional","affiliation":[{"name":"Real World Data Science, Product Development Data Sciences, F. Hoffmann-La Roche Ltd , Basel 4070 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, International Centre for Thoracic Cancers (CICT) , Gustave Roussy, Villejuif 94800 ,","place":["France"]},{"name":"Faculty of Medicine, Paris Saclay University , Kremlin-Bic\u00eatre 94270 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Eun Kim","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine , Seoul 05505 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Precision Oncology Institution, Medical College of Wisconsin (MCW) Cancer Center , Milwaukee, WI 53226 ,","place":["United States"]},{"name":"Medical Oncology, University of Nebraska , Omaha, NE 68182 ,","place":["United States"]},{"name":"Worldwide Innovative Network (WIN) for Personalized Cancer Therapy , Chevilly-Larue 94550 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre for Molecular Oncology, University of New South Wales , Sydney, New South Wales 2033 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Jagtiani","sequence":"additional","affiliation":[{"name":"Product Development, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Noe","sequence":"additional","affiliation":[{"name":"TM Oncology, F. Hoffmann-La Roche Ltd , Basel 4070 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schwemmers","sequence":"additional","affiliation":[{"name":"Global Product Development Medical Affairs (PDMA), F. Hoffmann-La Roche Ltd , Basel 4070 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-2562","authenticated-orcid":false,"given":"Christos","family":"Nikolaidis","sequence":"additional","affiliation":[{"name":"Product Development, F. Hoffmann-La Roche Ltd , Basel 4070 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"2025050809492614400_CIT0001","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"key":"2025050809492614400_CIT0002","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte","year":"2018","journal-title":"Mol Cancer."},{"key":"2025050809492614400_CIT0003","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis Oncol."},{"key":"2025050809492614400_CIT0004","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1634\/theoncologist.2016-0488","article-title":"ALK fusions in a wide variety of tumor types respond to anti-ALK targeted therapy","volume":"22","author":"Ross","year":"2017","journal-title":"Oncologist."},{"key":"2025050809492614400_CIT0005","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/cancers10070224","article-title":"Current molecular-targeted therapies in NSCLC and their mechanism of resistance","volume":"10","author":"Schrank","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025050809492614400_CIT0006","author":"Administration UFD","year":"2023"},{"key":"2025050809492614400_CIT0007","author":"European Medicines Agency (EMA)"},{"key":"2025050809492614400_CIT0008","author":"Administration UFD","year":"2021"},{"key":"2025050809492614400_CIT0009","author":"European Medicines Agency (EMA)"},{"key":"2025050809492614400_CIT0010","author":"Administration UFD","year":"2024"},{"key":"2025050809492614400_CIT0011","author":"European Medicines Agency (EMA)"},{"key":"2025050809492614400_CIT0012","author":"Administration UFD","year":"2022"},{"key":"2025050809492614400_CIT0013","author":"European Medicines Agency (EMA)"},{"key":"2025050809492614400_CIT0014","author":"Administration UFD","year":"2021"},{"key":"2025050809492614400_CIT0015","author":"European Medicines Agency (EMA)"},{"key":"2025050809492614400_CIT0016","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med."},{"key":"2025050809492614400_CIT0017","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA."},{"key":"2025050809492614400_CIT0018","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol."},{"key":"2025050809492614400_CIT0019","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/jep.12072","article-title":"Using balance statistics to determine the optimal number of controls in matching studies","volume":"19","author":"Linden","year":"2013","journal-title":"J Eval Clin Pract."},{"key":"2025050809492614400_CIT0020","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2307\/2529981","article-title":"Bias reduction using Mahalanobis-metric matching","volume":"36","author":"Rubin","year":"1980","journal-title":"Biometrics."},{"key":"2025050809492614400_CIT0021","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1037\/a0019623","article-title":"Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research","volume":"15","author":"Harder","year":"2010","journal-title":"Psychol Methods."},{"key":"2025050809492614400_CIT0022","doi-asserted-by":"publisher","first-page":"e2300334","DOI":"10.1200\/PO.23.00334","article-title":"Characteristics and survival outcomes of patients with metastatic RET fusion-positive solid tumors receiving non-RET inhibitor standards of care in a real-world setting","volume":"8","author":"Hackshaw","year":"2024","journal-title":"JCO Precision Oncol."},{"key":"2025050809492614400_CIT0023","doi-asserted-by":"publisher","first-page":"\/j\/ijb.2012.8.issue","DOI":"10.1515\/1557-4679.1312","article-title":"Survival curve estimation with dependent left truncated data using Cox\u2019s model","volume":"8","author":"Mackenzie","year":"2012","journal-title":"Int J Biostat."},{"key":"2025050809492614400_CIT0024","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/cancers13040597","article-title":"TP53 mutations as a driver of metastasis signaling in advanced cancer patients","volume":"13","author":"Pandey","year":"2021","journal-title":"Cancers"},{"key":"2025050809492614400_CIT0025","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.lungcan.2018.05.020","article-title":"Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer","volume":"122","author":"Chaft","year":"2018","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"2025050809492614400_CIT0026","doi-asserted-by":"publisher","first-page":"113278","DOI":"10.1016\/j.ejca.2023.113278","article-title":"Modified study designs to expand treatment options in personalised oncology: a multistakeholder view","volume":"194","author":"Le Tourneau","year":"2023","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"2025050809492614400_CIT0027","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3390\/life11111253","article-title":"Master protocols for precision medicine in oncology: overcoming methodology of randomized clinical trials","volume":"11","author":"Di Liello","year":"2021","journal-title":"Life (Basel, Switzerland)"},{"key":"2025050809492614400_CIT0028","doi-asserted-by":"publisher","first-page":"CT032","DOI":"10.1158\/1538-7445.am2022-ct032","article-title":"Activity and safety of alectinib for ALK-altered solid tumors from MyPathway","volume":"82","author":"Swanton","year":"2022","journal-title":"Cancer Res."},{"key":"2025050809492614400_CIT0029","doi-asserted-by":"publisher","first-page":"TPS3154","DOI":"10.1200\/jco.2021.39.15_suppl.tps3154","article-title":"Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): a novel platform umbrella trial","volume":"39","author":"Drilon","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025050809492614400_CIT0030","doi-asserted-by":"publisher","first-page":"CT039","DOI":"10.1158\/1538-7445.am2024-ct039","article-title":"Abstract CT039: alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: data from the iMATRIX Alectinib Phase I\/II open-label, multi-center study","volume":"84","author":"Doz","year":"2024","journal-title":"Cancer Res."},{"key":"2025050809492614400_CIT0031","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11523-021-00815-4","article-title":"TRK fusion cancer: patient characteristics and survival analysis in the real-world setting","volume":"16","author":"Bazhenova","year":"2021","journal-title":"Target Oncol."},{"key":"2025050809492614400_CIT0032","doi-asserted-by":"publisher","first-page":"e0270571","DOI":"10.1371\/journal.pone.0270571","article-title":"Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors","volume":"17","author":"Hibar","year":"2022","journal-title":"PLoS One."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf005\/63126921\/oyaf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf005\/63126921\/oyaf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:49:34Z","timestamp":1746712174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf005\/8126963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf005","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf005"}}